KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Orszagos Koranyi Pulmonologiai Intezet ( Site 0060), Budapest

Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061), Szolnok

Petz Aladar Megyei Oktato Korhaz ( Site 0062), Győr

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0034), New York

Seoul National University Bundang Hospital ( Site 0081), Seongnam-si

Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia

Georgetown University ( Site 0036), Washington D.C.

IRCCS Ospedale San Raffaele ( Site 0171), Milan

MedStar Franklin Square Medical Center ( Site 0033), Baltimore

Hospital Universitario Quiron Madrid ( Site 0091), Madrid

Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus

Cleveland Clinic Main ( Site 0006), Cleveland

Azienda Ospedaliera Universitaria Careggi ( Site 0173), Florence

Sanford Cancer Center ( Site 0038), Sioux Falls

Sanford Fargo Medical Center ( Site 0039), Fargo

Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031), Omaha

The University of Texas MD Anderson Cancer Center ( Site 0009), Houston

Banner MD Anderson Cancer Center ( Site 0001), Gilbert

City of Hope ( Site 0014), Duarte

UCSF Medical Center at Mission Bay ( Site 0007), San Francisco

Rambam Health Care Campus-Oncology ( Site 0076), Haifa

Meir Medical Center ( Site 0071), Kfar Saba

Rabin Medical Center ( Site 0074), Petah Tikva

Chaim Sheba Medical Center ( Site 0070), Ramat Gan

Sourasky Medical Center ( Site 0077), Tel Aviv

Soroka Medical Center ( Site 0072), Beersheba

Shaare Zedek Medical Center ( Site 0075), Jerusalem

University of Kentucky Markey Cancer Center ( Site 0019), Lexington

Massachusetts General Hospital ( Site 0003), Boston

Dana Farber Cancer Institute ( Site 0002), Boston

Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037), Hackensack

Policlinico Gemelli di Roma ( Site 0174), Roma

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 0151), Warsaw

Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150), Gdansk

Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152), Koszalin

Severance Hospital ( Site 0080), Seoul

Samsung Medical Center ( Site 0082), Seoul

ICO L Hospitalet ( Site 0090), L'Hospitalet de Llobregat